Official Journal of Research Center for Gastroenterology and Liver Diseases
Scopus by Title (Ref)
Articles that cite the referenced work, matched by title from the Scopus database.
Cost-utility analysis of Edaravone compared to Riluzole in patients with amyotrophic lateral sclerosis (ALS) in Iran
Cost Effectiveness and Resource Allocation
December 2026
Omranikhoo H.
Open Access
Cost-Effectiveness of Dimethyl Fumarate Versus Teriflunomide in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) in Iran
Health Science Reports
April 2026
Poursadeghfard M.
Open Access
A cost-utility analysis of Glecaprevir/Pibrentasvir versus Sofosbuvir/Daclatasvir and Sofosbuvir/Velpatasvir for treatment of hepatitis C in Iran
Cost Effectiveness and Resource Allocation
December 2025
Jafari M.
Open Access
Budget impact analysis of glecaprevir/pibrentasvir treatment for hepatitis C in Iran: a modelling study
BMJ Open
11 September 2025
Jafari M.
Open Access
Decision-Analytical Modelling of Medicines in the Middle East: A Systematic Review of Economic Evaluation Studies
Applied Health Economics and Health Policy
July 2025
Abdali Z.
Cost-effectiveness Analysis of Triptorelin, Goserelin, and Leuprolide in the Treatment of Patients with Metastatic Prostate Cancer: A Societal Perspective
Value in Health Regional Issues
July 2024
Rezaee M.
Open Access
Cost-Effectiveness Analysis of Pharmacogenomics-Guided Versus Standard Dosing of Warfarin in Patients with Mechanical Prosthetic Heart Valve
Iranian Journal of Pharmaceutical Research
2024
Hemati H.
Open Access
Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis
BMC Health Services Research
December 2022
Rezaee M.
Open Access
A Systematic Review on Economic Evaluation Studies of Diagnostic and Therapeutic Interventions in the Middle East and North Africa
Applied Health Economics and Health Policy
May 2022
Nagi M.A.
QALY league table of Iran: a practical method for better resource allocation
Cost Effectiveness and Resource Allocation
December 2021
Hashempour R.
Open Access
Cost-utility Analysis of Second-generation Direct-acting Antivirals for Hepatitis C
Hepatitis Monthly
Aug 2021
Goudarzi Z.
Open Access
Cost-Effectiveness Analysis of Biopharmaceuticals for Treating Rheumatoid Arthritis: Infliximab, Adalimumab, and Etanercept
Biomed Research International
2021
Gholami A.
Open Access
Are Published Health Economic Models for Chronic Hepatitis B Appropriately Capturing the Benefits of HBsAg Loss? A Systematic Literature Review
Pharmacoeconomics Open
1 September 2020
Wigfield P.
Open Access